Ascendis Pharma As Stock In The News
| ASND Stock | USD 122.64 1.74 1.40% |
Our overall analysis of Ascendis Pharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Ascendis Pharma AS. The specific impact of Ascendis Pharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Ascendis Pharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Ascendis Pharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Ascendis Pharma Backtesting and Ascendis Pharma Hype Analysis.
Ascendis |
Ascendis Pharma Today Top News and Investor Outlook
Ascendis Pharma AS Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Ascendis and other traded companies coverage with news coverage. We help investors stay connected with Ascendis headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Ascendis Stock performance. Please note that trading solely based on the Ascendis Pharma AS hype is not for everyone as timely availability and quick action are needed to avoid losses.
Ascendis Pharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Ascendis earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Ascendis Pharma that are available to investors today. That information is available publicly through Ascendis media outlets and privately through word of mouth or via Ascendis internal channels. However, regardless of the origin, that massive amount of Ascendis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ascendis Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ascendis Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ascendis Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ascendis Pharma alpha.
Ascendis Largest EPS Surprises
Earnings surprises can significantly impact Ascendis Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-23 | 2017-03-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2016-04-14 | 2016-03-31 | -0.46 | -0.54 | -0.08 | 17 | ||
2016-08-31 | 2016-06-30 | -0.69 | -0.6 | 0.09 | 13 | ||
2018-03-28 | 2017-12-31 | -0.8 | -0.92 | -0.12 | 15 | ||
2016-11-30 | 2016-09-30 | -0.68 | -0.8 | -0.12 | 17 | ||
2022-05-11 | 2022-03-31 | -2 | -2.21 | -0.21 | 10 |
Ascendis Pharma Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Ascendis Pharma AS Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
20th of November 2024
Ascendis Pharma AS Upgraded by StockNews.com to Hold Rating - MarketBeat at news.google.com
15th of November 2024
TD Cowen cuts Ascendis Pharma target to 153, keeps buy rating at investing.com
14th of November 2024
T. Rowe Price Investment Management, Inc. Expands Holdings in Ascendis Pharma AS at gurufocus.com
13th of November 2024
Finepoint Capital LPs Strategic Acquisition of QXO Inc Shares at gurufocus.com
7th of November 2024
Equities Analysts Set Expectations for ASND Q3 Earnings at thelincolnianonline.com
6th of November 2024
Royalty Pharma Reports Third Quarter 2024 Results at finance.yahoo.com
5th of November 2024
Novo Nordisk Secures License for Ascendis Pharmas Obesity Drug Technology at finance.yahoo.com
4th of November 2024
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs at finance.yahoo.com
1st of October 2024
Ascendis Pharma submits sBLA for growth hormone deficiency therapy at finance.yahoo.com
17th of September 2024
Ascendis Soars on Encouraging Data From Dwarfism Drug Study at zacks.com
5th of September 2024
Ascendis Pharma AS Q2 2024 Earnings Call Transcript at insidermonkey.com
Ascendis Pharma Investors Sentiment
The influence of Ascendis Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ascendis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Ascendis Pharma's public news can be used to forecast risks associated with an investment in Ascendis. The trend in average sentiment can be used to explain how an investor holding Ascendis can time the market purely based on public headlines and social activities around Ascendis Pharma AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ascendis Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ascendis Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ascendis Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ascendis Pharma.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ascendis Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ascendis Pharma's short interest history, or implied volatility extrapolated from Ascendis Pharma options trading.
Check out Ascendis Pharma Backtesting and Ascendis Pharma Hype Analysis. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.91) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.